Operating profit before amortization: bioAffinity Technologies (BIAF)

bioAffinity Technologies' reliance on external clinics for biomaterial collection creates operational risks, which is reflected in the absolute EBITDA trend. The value 0.00 shows the current magnitude of this metric. However, management's focus on evidence-based diagnostics and the growing demand from US oncology centers for non-invasive tests create significant potential for the commercial scaling of the business.

The specific nature of bioAffinity Technologies (BIAF), which brings together cytometry experts for cancer diagnostics, makes monitoring operating profit in cash terms a key tool for assessing the efficiency of scientific grant utilization. This indicator captures the net cash flow from core operations, excluding depreciation and credit obligations, allowing investors to determine the business's actual ability to generate cash and justify the asset's current market value.